Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Contributed by: Business Wire

Logo

Tags

Health

Biotechnology

Silence Therapeutics plc

More Like This

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease